Season 2 (2021-2030)

Ophthalmology - Discovery (26)

Modality Indication Targets Stage Company Project No. Detail
1 Development of first-in-class drugs to treat Leber’s hereditary optic neuropathy (LHON)
Small molecules LHON Mitochondrial chaperone Hit UNIST RS-2025-25455041
2 Development of ○○○ inhibitor as a novel therapy for AgedMacular degeneration
Small molecules wet age-related macular degeneration (wAMD) N/A Hit Gachon University RS-2024-00332803
3 Development of new compounds for effective gene editing therapy for an IMPDH1 mutation causing autosomal dominant retinitis pigmentosa
Gene & Nucleic acids Retinitis Pigmentosa IMPDH1 Hit Ulsan University RS-2023-00283544
4 Development of AAV based ocular cell/tissue targeting technology and treatment candidates for the development of gene therapy for X.chromosome.linked retinitis pigmentosa
Gene & Nucleic acids Retinitis Pigmentosa RPGR Hit ENCell RS-2023-00258840
5 Retinal regenerative antibody and gene therapy
Antibody Degenerative Retinal Disease PROX1 Hit CELLIAZ RS-2023-00258166
6 Lead identification for retinal diseases using selective NO delivery compounds
Small molecules Retinal vein occlusion Co, Fe Hit Ulsan National Institute of Science & Technology RS-2023-00217242
7 Development of gene therapeutics targeting EYS-related Retinitis Pigmentosa
Gene & Nucleic acids Retinitis pigmentosa EYS c.4957dupA Hit Sungkyunkwan University HN22C0571
8 Development of novel gene therapy for PDE6B related inherited retinal disease
Gene & Nucleic acids Genetic Retinal disease PDE6B Hit Asan Medical Center HN22C0245
9 To develop the lead of a new oral drug for age-related macular degeneration
Small molecules Age-related macular degeneration PDK4 Hit Kyungpook National University HN21C0923
10 Lead generation of prime editor for genetic variants of Leber congenital amaurosis
Gene & Nucleic acids Leber Congenital Amaurosis CEP290 Hit Seoul National University HN21C0917
11 Lead development of orally available drug for diabetic retinopathy targeting TGase 2 to inhibit vascular leakage
Small molecules Diabetic retinopathy TGase2 Hit Daegu Gyyeongbuk Medical Innovation Foundation HN21C1155
12 Development of Retina-Specific AAV and Gene-Editing Therapeutics for Leber Congenital Amaurosis type 10 based on the TaRGET System
Gene & Nucleic acids Leber’s congenital amaurosis 10 CEP290 Lead GenKOre RS-2024-00339507
13 Development of inflammatory cell-targeting exosome-based therapeutics for Ophthalmology via **** inhibition
rProtein Confidential N/A Lead ILIAS Biologics RS-2024-00337789
14 Development of recombinant protein targeting human complement C5 for dry age.related macular degeneration treatment
Antibody Macular degeneration Human Complement C5 Lead Immunabs Co., Ltd. RS-2023-00282906
15 Development of lead compound for Leber hereditary optic neuropathy
Small molecules Leber hereditary optic neuropathy NQO1 Lead Curome Bioscience RS-2023-00259507
16 Discovery of first-in-Class AMD treatment for dry eye using Autophagy activation
Small molecules Dry macular degeneration Autophage Lead VasThera RS-2022-00166507
17 Development of multi-specific fusion protein modulating multiple angiogenesis pathways for the treatment of retinal vascular diseases
rProtein wAMD, DME, DR VEGF-A, VEGF-B, PlGF, Ang-2 Candidate ALTEOGEN BIOLOGICS RS-2025-25449916
18 Discovery of an orally available pre-clinical candidate for age-related macular degeneration
Small molecules AMD PDK4 Candidate JD Bioscience Inc. RS-2025-25446266
19 The development of EFL-201 Eye drops for the treatment of presbyopia
Small molecules Presbyopia 렌즈단백질 Candidate eFlask.co.,Ltd. RS-2025-02223273
20 AAV Gene Therapy for Degenerative Retinal Diseases
Gene & Nucleic acids Dry-AMD(Age-related Macular Degeneration), Inherited retinal disease Nkx3.2 Candidate ICM CO., LTD. RS-2024-00344469
21 Development of a tri-functional bispecific antibody candidate activating Tie2 and inhibiting VEGF/Ang-2 for treating wet agerelated macular degeneration (wAMD)
Antibody Wet age-related macular degeneration (wAMD) Tie2, VEGF, Ang-2 Candidate MabTics Co., Ltd. RS-2024-00334041
22 Development of therapeutic candidate: Tie2 and Ang2 dual modulator for the next.generation treatment of wAMD and DR.
Antibody wet AMD/DR Ang2.targeting Tie2 receptor Candidate Neortesbio Co.,Ltd. RS-2023-00282960
23 Development of First.in.Class mutant transcript.selective ASO therapeutic candidates for the treatment of Avellino corneal dystrophy
Gene & Nucleic acids Avellino corneal dystrophy Human TGFBIR124H Candidate MediciBIO Co., LTD RS-2023-00282731
24 Recombinant human HAPLN1 protein: a multi-functional therapeutic candidate to treat dry eye disease
rProtein Dry eye disease HAPLN1 Candidate HaplnScience Inc. RS-2023-00217306
25 Discovery of Non-clinical Development Candidate Molecule for a Novel Universal Retinitis Pigmentosa Therapeutics
Gene & Nucleic acids Retinitis Pigmentosa RORβ Candidate OliX Pharmaceuticals RS-2023-00217014
26 Nonclinical drug candidates targeting TRAP1 to treat diabetic retinopathy
Small molecules Diabetic retinopathy TRAP1 Candidate SMARTIN BIO Inc. HN21C0882
BACK